LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Adenoviral Vectors for Gene Therapy
- 3rd Edition - February 1, 2025
- Editors: David T. Curiel, Alan L. Parker
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 8 2 1 - 8
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 8 1 4 - 1
Adenoviral Vectors for Gene Therapy, Third Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdenoviral Vectors for Gene Therapy, Third Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research.
The fully updated and expanded third edition covers the basic biology of adenoviruses, highlights the potential use adenoviral vectors for the treatment of disease including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for vet applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine application and virotherapy, and oncolytic adenoviruses for anti-tumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
The fully updated and expanded third edition covers the basic biology of adenoviruses, highlights the potential use adenoviral vectors for the treatment of disease including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for vet applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine application and virotherapy, and oncolytic adenoviruses for anti-tumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
- Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors
- Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement
- Demonstrates noninvasive imaging of adenovirus-mediated gene transfer
- Discusses utility of adenoviral vectors in animal disease models
- Considers Federal Drug Administration regulations for human clinical trials
Researchers in virology, genetics (specifically gene therapy) and others engaged in therapeutics research; "translational" physician-scientists will find this a unique resource for understanding the clinical issues of applying adenoviral vectors
1. Adenovirus Structure
2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms
3. Adenovirus Replication
4. Adenoviral Vector Construction I: Mammalian Systems
5. Adenoviral Vector Construction II: Bacterial Systems
6. Upstream Bioprocess for Adenovirus Vectors
7. Propagation of Adenoviral Vectors: Use of PER.C6™ Cells
8. Purification of Adenovirus
9. Targeted Adenoviral Vectors I: Transductional Targeting
10. Targeted Adenoviral Vectors III: Transcriptional Targeting
11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration
12. Molecular Design of Oncolytic Adenoviruses
13. Conditionally Replicative Adenoviruses—Clinical Trials
14. Innate Immune Response to Adenovirus Vector Administration In Vivo
15. Antibodies against Adenoviruses
16. Methods to Mitigate Immune Responses to Adenoviral Vectors
17. Helper-Dependent Adenoviral Vectors
18. Hybrid Adenoviral Vectors
19. Xenogenic Adenoviral Vectors
20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics
21. Adenoviral Vector Vaccines Antigen Transgene
22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen
23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer
24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer
25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease
26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease)
27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases
28. Animal Models of Gene Therapy for Cardiovascular Disease
29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy
30. Adenoviral Vectors for RNAi Delivery
31. Imaging and Adenoviral Gene Therapy
32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms
3. Adenovirus Replication
4. Adenoviral Vector Construction I: Mammalian Systems
5. Adenoviral Vector Construction II: Bacterial Systems
6. Upstream Bioprocess for Adenovirus Vectors
7. Propagation of Adenoviral Vectors: Use of PER.C6™ Cells
8. Purification of Adenovirus
9. Targeted Adenoviral Vectors I: Transductional Targeting
10. Targeted Adenoviral Vectors III: Transcriptional Targeting
11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration
12. Molecular Design of Oncolytic Adenoviruses
13. Conditionally Replicative Adenoviruses—Clinical Trials
14. Innate Immune Response to Adenovirus Vector Administration In Vivo
15. Antibodies against Adenoviruses
16. Methods to Mitigate Immune Responses to Adenoviral Vectors
17. Helper-Dependent Adenoviral Vectors
18. Hybrid Adenoviral Vectors
19. Xenogenic Adenoviral Vectors
20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics
21. Adenoviral Vector Vaccines Antigen Transgene
22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen
23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer
24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer
25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease
26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease)
27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases
28. Animal Models of Gene Therapy for Cardiovascular Disease
29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy
30. Adenoviral Vectors for RNAi Delivery
31. Imaging and Adenoviral Gene Therapy
32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
- No. of pages: 900
- Language: English
- Edition: 3
- Published: February 1, 2025
- Imprint: Academic Press
- Hardback ISBN: 9780323898218
- eBook ISBN: 9780323958141
DC
David T. Curiel
David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.
Affiliations and expertise
Washington University School of Medicine, St. Louis, MO, USAAP
Alan L. Parker
Affiliations and expertise
Professor of Translational Virotherapies, Head of Section of Solid Cancers, Division of Cancer and Genetics, University of Cardiff, UK